姜黄素
生物利用度
姜黄
可药性
药理学
医学
药品
传统医学
化学
生物化学
基因
作者
Min Hao,Ying‐Hao Chu,Lei Jing-xuan,Zhouhui Yao,Pingping Wang,Ziyan Chen,Kuilong Wang,Xianan Sang,Xin Han,Lu Wang,Gang Cao
标识
DOI:10.14336/ad.2022.1101
摘要
Curcumin, a well-known hydrophobic polyphenol extracted from the rhizomes of turmeric (Curcuma longa L.), has attracted great interest in the last ten years due to its multiple pharmacological activities. A growing body of evidence has manifested that curcumin has extensive pharmacological activities including anti-inflammatory, anti-oxygenation, lipid regulation, antiviral, and anticancer with hypotoxicity and minor adverse reactions. However, the disadvantages of low bioavailability, short half-life in plasma, low drug concentration in blood, and poor oral absorption severely limited the clinical application of curcumin. Pharmaceutical researchers have carried out plenty of dosage form transformations to improve the druggability of curcumin and have achieved remarkable results. Therefore, the objective of this review summarizes the pharmacological research progress, problems in clinical application and the improvement methods of curcumin's druggability. By reviewing the latest research progress of curcumin, we believe that curcumin has a broad clinical application prospect for its wide range of pharmacological activities with few side effects. The deficiencies of lower bioavailability of curcumin could be improved by dosage form transformation. However, curcumin in the clinical application still requires further study regarding the underlying mechanism and clinical trial verification.
科研通智能强力驱动
Strongly Powered by AbleSci AI